CANC Among Its Peers
End-of-day Nov 20, 2026 · 1 ETFs by 1Y
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| Total return | −2.1% | −8.6% | −9.6% | −15.4% | +8.1% | +10.6% | +69.9% | — | — | +58.6% |
| S&P 500 · VOO | −3.4% | −8.3% | −9.5% | −9.2% | +2.2% | +5.5% | +59.8% | +58.7% | +275.8% | — |
$65 of every $1,000 in CANC is Genmab
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S | Healthcare | 6.47% | $646.98 | 249K | $12.8M |
| 2 | RVMDRevolution Medicines | Healthcare | 5.54% | $553.65 | 69K | $10.9M |
| 3 | LLYELI Lilly | Healthcare | 5.13% | $512.74 | 7,504 | $10.1M |
| 4 | COGTCogent Biosciences | Healthcare | 4.47% | $446.89 | 319K | $8.8M |
| 5 | ONCBeone Medicines | Healthcare | 4.45% | $444.94 | 22K | $8.8M |
| 6 | MRKMerck | Healthcare | 4.36% | $435.50 | 65K | $8.6M |
| 7 | EXELExelixis | Healthcare | 3.82% | $381.51 | 115K | $7.5M |
| 8 | CGONCG Oncology | Healthcare | 3.76% | $375.97 | 91K | $7.4M |
| 9 | NOVN.SWNovartis AG | Healthcare | 3.74% | $373.82 | 49K | $7.4M |
| 10 | ABBVAbbvie | Healthcare | 3.48% | $348.00 | 24K | $6.9M |
| 11 | BBIOBridgebio Pharma | Healthcare | 3.42% | $341.69 | 86K | $6.8M |
| 12 | RHHBYRoche AG | Healthcare | 3.36% | $336.08 | 113K | $6.6M |
| 13 | ELVNEnliven Therapeutics | Healthcare | 3.06% | $306.47 | 131K | $6.1M |
| 14 | HALOHalozyme Therapeutics | Healthcare | 2.99% | $299.34 | 64K | $5.9M |
| 15 | BMYBristol-myers Squibb | Healthcare | 2.49% | $249.02 | 84K | $4.9M |
CANC has no close peers in our data yet: […]
No peers with a full year of prices to rank against yet.
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S | 6.47% |
| 2 | RVMD | Revolution Medicines | 5.54% |
| 3 | LLY | ELI Lilly & | 5.13% |
| 4 | COGT | Cogent Biosciences | 4.47% |
| 5 | ONC | Beone Medicines | 4.45% |
| 6 | MRK | Merck & | 4.36% |
| 7 | EXEL | Exelixis | 3.82% |
| 8 | CGON | CG Oncology | 3.76% |
| 9 | NOVN.SW | Novartis AG | 3.74% |
| 10 | ABBV | Abbvie | 3.48% |
| Fund | Sharpe | Sortino | Volatility | Max DD | Beta | Fee / $10k |
|---|---|---|---|---|---|---|
| CANC | 0.33 | 0.50 | 24.4% | −17.1% | 0.80 | $99 |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 10, 2025 | Dec 11, 2025 | $0.0196 |
| Dec 11, 2024 | Dec 12, 2024 | $0.73 |
| Dec 13, 2023 | Dec 15, 2023 | $0.15 |